Clinical Updates

Recent Clinical Updates

Search and filter HCP Connect coverage by specialty, drug topic, reference, or clinical keyword.

Clinical Coverage

Search clinical updates and clinical coverage.

12 loaded

Endocrinology

FDA Approves Tzield for Type 1 Diabetes: Delays Onset in Pediatric Patients

Tzield (teplizumab) delays onset of Stage 3 Type 1 diabetes in pediatric patients aged 8 to 17 years.

Jun 15|4 min read|Dr. Amit Desai

Rheumatoid Arthritis

FDA Approves First Biosimilar to Actemra: Tofidence for Rheumatoid Arthritis

FDA approves Tofidence for rheumatoid arthritis, the first biosimilar to Actemra, enhancing access to effective therapies.

Jun 14|4 min read|Editorial Team

Pulmonology

Asthma Triple Inhaler Therapy: Patient Selection Criteria for Trimbow, Trelegy, and Breztri

Asthma triple inhaler therapy: Patient selection criteria for Trimbow, Trelegy, and Breztri in severe asthma management.

Jun 14|4 min read|Dr. Nikhil Chatterjee

Rheumatology

FDA Approves Immgolis for Rheumatoid Arthritis and Ulcerative Colitis: First Interchangeable Biosimilar to Simponi

Immgolis (golimumab-sldi) approved for rheumatoid arthritis and ulcerative colitis: first interchangeable biosimilar to Simponi.

Jun 14|4 min read|Dr. Deepak Nair

Oncology

FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer

Camizestrant: FDA panel votes against approval for ESR1-mutated breast cancer treatment.

Jun 14|4 min read|Dr. Meera Pillai

Dermatology

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% sPGA Response in BE VIVID Trial

Bimekizumab (Bimzelx) approved for moderate to severe plaque psoriasis: 75% sPGA response in BE VIVID trial.

Jun 14|4 min read|Dr. Divya Agarwal

Endocrinology

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

Semaglutide reduces cardiovascular risk by 20% in the SELECT trial, now FDA approved for adults with obesity and cardiovascular disease.

Jun 13|4 min read|Dr. Amit Desai

Endocrinology

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

Tirzepatide (Zepbound) approved for chronic weight management: 18% weight reduction in SURMOUNT-1 trial.

Jun 13|4 min read|Dr. Amit Desai

Oncology

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

Imlunestrant reduces PFS by 5.5 months in ESR1-mutated breast cancer.

Jun 13|4 min read|Dr. Meera Pillai

Cardiology

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

Baxdrostat: 10 mmHg SBP reduction in resistant hypertension from the BaxHTN trial. FDA approval confirmed.

Jun 13|4 min read|Dr. Kavya Sharma

Oncology

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Camizestrant for ESR1-mutated breast cancer: FDA advisory panel evaluates efficacy and safety for HR-positive patients.

Jun 13|4 min read|Dr. Meera Pillai

Endocrinology

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

FDA approves Jubbonti for osteoporosis treatment: an interchangeable biosimilar to Prolia, enhancing access to effective management.

Jun 13|4 min read|Dr. Amit Desai